Articles

[The purpose of this study was to evaluate the efficacy, effect profile, and safety of dexamethasone implant on diabetic macular edema (DME) in a real-life setting, further comparing results by DME duration, previous treatment status, and diabetic control.]

Available with an NHS OpenAthens password for eligible users

[Developmentally sensitive measures of vision-related quality of life (VQoL) are needed to capture age-specific concerns about the impact of living with visual impairment (VI) in children and young people. Our objective was to use our validated VQoL instrument for children and young people 10 to 15 years of age (the VQoL_CYP) as the foundation for development of age-specific extensions.]

Available with an NHS OpenAthens password for eligible users

[There is no level I evidence to support the use of binocular treatment as a substitute for current therapies for amblyopia (including patching and optical treatment). Furthermore, 2 large randomized controlled trials showed inferior performance compared with standard patching treatment. On the basis of this review of the published literature, binocular therapy cannot be recommended as a replacement for standard amblyopia therapy.]

Available with an NHS OpenAthens password for eligible users

[Collapsin response-mediator protein 5 (CRMP5) immunoglobulin G (IgG) has been associated with paraneoplastic optic neuritis, vitritis, retinitis, or a combination thereof, but few reports of these findings exist in the literature. We reviewed the neuro-ophtalmic findings and visual outcomes in a large series of CRMP5 IgG–positive patients to characterize further its clinical phenotype and response to treatment.]

Available with an NHS OpenAthens password for eligible users

[Geographic atrophy (GA), a late stage of age-related macular degeneration (AMD), is a major cause of blindness. Even while central visual acuity remains relatively well preserved, GA often causes}
considerable compromise of visual function and quality of life. No treatment currently exists. We evaluated the safety and efficacy of pegcetacoplan, a complement C3 inhibitor, for treatment of GA. Available with an NHS OpenAthens password for eligible users

**Deep learning approaches predict glaucomatous visual field damage from OCT optic nerve head en face images and retinal nerve fiber layer thickness maps.**
[The purpose of this study was to develop and evaluate a deep learning system for differentiating between eyes with and without glaucomatous visual field damage (GVFD) and predicting the severity of GFVD from spectral domain OCT (SD OCT) optic nerve head images.] Available with an NHS OpenAthens password for eligible users

**Differential effects of aging in the macular retinal layers, neuroretinal rim, and peripapillary retinal nerve fiber layer.**
[In this cross-sectional, multicenter study, the authors determined the differential aging effects of the inner 6 layers of the macula in contrast to the minimum neuroretinal rim width (MRW) and peripapillary retinal nerve fiber layer (RNFL) thickness. In concordance with histopathologic studies showing age-related loss of retinal ganglion cell axons, we showed a significant decline in GCL thickness, as well as MRW and peripapillary RNFL thickness.] Available with an NHS OpenAthens password for eligible users

[Acute-onset endophthalmitis occurred in 0.04% of 8,542,838 cataract surgeries performed in the United States between 2013 and 2017. Risk factors may include younger age, cataract surgery combined with other ophthalmic surgeries, and anterior vitrectomy. Visual acuity outcomes vary; however, patients can recover excellent vision after surgery. Big data from clinical registries like the IRIS Registry has great potential for evaluating rare conditions such as endophthalmitis.] Available with an NHS OpenAthens password for eligible users

**Incidence rate of herpes zoster ophthalmicus: a retrospective cohort study from 1994 through 2018.**
[The purpose of this retrospective, observational cohort study was to analyze the incidence rate (IR) of herpes zoster ophthalmicus (HZO) and differences by age, gender, race, and region from 1994 through 2018.] Available with an NHS OpenAthens password for eligible users

**Incomplete retinal pigment epithelial and outer retinal atrophy in age-related macular degeneration: classification of atrophy meeting report 4.**
[The purpose of this study was to describe the defining features of incomplete retinal pigment
epithelium (RPE) and outer retinal atrophy (iRORA), a consensus term referring to the OCT-based anatomic changes often identified before the development of complete RPE and outer retinal atrophy (cRORA) in age-related macular degeneration (AMD). We provide descriptive OCT and histologic examples of disease progression.

Available with an NHS OpenAthens password for eligible users

Intravitreal combined aflibercept + anti–platelet-derived growth factor receptor β for neovascular age-related macular degeneration: results of the phase 2 CAPELLA trial.
[The purpose of this randomized, double-masked study was to compare the efficacy and safety of intravitreal aflibercept + anti–platelet-derived growth factor receptor β (PDGFRβ) combination with intravitreal aflibercept injection (IAI) monotherapy in patients with treatment-naïve neovascular age-related macular degeneration (nAMD).]
Available with an NHS OpenAthens password for eligible users

Long-term outcomes of treatment with biological agents in eyes with refractory, active, noninfectious intermediate uveitis, posterior uveitis, or panuveitis.
[The purpose of this retrospective study was to examine a large cohort of patients treated with biologic agents for active noninfectious intermediate uveitis, posterior uveitis, or panuveitis (NIPPU) and to compare their efficacy and long-term effect.]
Available with an NHS OpenAthens password for eligible users

Macular atrophy in neovascular age-related macular degeneration: a randomized clinical trial comparing ranibizumab and aflibercept (RIVAL study)
[The purpose of the randomized, partially masked, multicenter study was to investigate differences in the development of macular atrophy (MA) over 24 months between treat-and-extend (T&E) ranibizumab and aflibercept in patients with neovascular age-related macular degeneration (nAMD).]
Available with an NHS OpenAthens password for eligible users

Patterns of vitamin D levels and exposures in active and inactive noninfectious uveitis patients.
[Participants with active uveitis showed significantly lower serum 25-hydroxy vitamin D levels than inactive uveitis patients and local population-based estimates. Vitamin D supplementation was found to be associated with decreased uveitis activity, as was sun exposure in those with vitamin D deficiency. These results suggest that vitamin D supplementation should be studied as an option for the prevention of uveitis relapse in at-risk patients.]
Available with an NHS OpenAthens password for eligible users

Predicting the prognosis of Fuchs endothelial corneal dystrophy by using Scheimpflug tomography.
[The purpose of this disease was to determine if Scheimpflug tomography pachymetry map and
posterior elevation map patterns, central corneal thickness (CCT), and corneal backscatter can predict the prognosis of Fuchs endothelial corneal dystrophy (FECD).

Available with an NHS OpenAthens password for eligible users

**Sex-specific differences in circumpapillary retinal nerve fiber layer thickness.**
Li D. *Ophthalmology* 2020;127(3):357-368.
[Substantial sex effects on cRNFL thickness were found at 56.8% of all 768 circumpapillary locations, with specific patterns for different sectors. Over large regions, sex was at least as important in explaining the cRNFL thickness variance as was age, which is well established to have a substantial impact on cRNFL thickness. Including sex in the cRNFL thickness norm could therefore improve glaucoma diagnosis and monitoring.]
Available with an NHS OpenAthens password for eligible users

**Treatment outcomes in the primary tube versus trabeculectomy study after 3 Years of follow-up.**
[There was no significant difference in the rate of surgical failure between the 2 surgical procedures at 3 years. Trabeculectomy with MMC achieved lower IOP with use of fewer glaucoma medications compared with tube shunt surgery after 3 years of follow-up in the PTVT Study. Serious complications producing vision loss or requiring reoperation occurred with similar frequency after both surgical procedures.]
Available with an NHS OpenAthens password for eligible users

**Treatment outcomes of ranibizumab versus aflibercept for neovascular age-related macular degeneration: data from the Fight Retinal Blindness! Registry**
[Ranibizumab and aflibercept are both approved for the treatment of neovascular age-related macular degeneration (nAMD). Herein, we compare the 3-year treatment outcomes of the 2 in routine clinical practice.]
Available with an NHS OpenAthens password for eligible users

**Guideline**

**Viral conjunctivitis and COVID-19.**
College of Optometrists; 2020.
[A joint statement from The Royal College of Ophthalmologists and College of Optometrists. Updated 19 May.]
Freely available online
This Bulletin was created by Liz Wright of NHS East Dorset Knowledge and Library Service

Need further help? The NHS Library & Knowledge Team is here to support the information needs of all NHS staff across Dorset. We’re happy to help you with literature searches, search skills training and advice, keeping you up to date, and general references enquiries.

Contact us:
Telephone: 01202 442101/01202 704270
library@poole.nhs.uk library@rbch.nhs.uk
https://dorsetnhs.libguides.com

Register for OpenAthens to access e-resources: https://openathens.nice.org.uk/

To subscribe/unsubscribe from this bulletin please reply to the email.

By signing up to receive this bulletin, you agree that the information provided (your email address and name) will be held on NHS East Dorset Library and Knowledge Service files or databases. You will only be contacted by us in reference to this bulletin. By submitting this information you agree that your details may be used for this purpose. Your details will not be passed on to any third parties.